Employers and employees beset by fears over what prescription drug price increases are doing to their bottom lines and their health have some unexpected allies.
An asset manager and member of the the Interfaith Center on Corporate Responsibility has submitted drug pricing proposals to Merck & Co. and Gilead Sciences concerning their price increases.
Azzad Asset Management, advisor to the Azzad Funds, along with other members of the ICCR, have filed resolutions this year with 11 major U.S. pharmaceutical companies and sent letters to an additional six non-U.S. companies advocating a reasoned and fair reassessment of pricing policy.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
